Beyond Air (XAIR) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
30 Oct, 2026Executive summary
Annual meeting scheduled for Dec. 10, 2026, at 4:30 p.m. ET; voting deadline is Dec. 9, 2026, at 11:59 p.m. ET.
Proxy statement and Form 10-K available online; paper or email copies could be requested by Nov. 26, 2026.
Voting matters and shareholder proposals
Four matters are on the ballot: elect five directors, ratify the auditor, approve an advisory say-on-pay vote, and authorize adjournment or postponement if quorum or additional votes are needed; Board recommends For each.
Board of directors and corporate governance
Nominees Robert S. Goodman, Robert F. Carey, Dr. William Forbes, Yoori Lee, and Erick J. Lucera would serve until the next annual meeting and until successors are elected and qualified.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Beyond Air
- Record LungFit PH revenue lifts guidance, but funding needs and FDA timing remain risks.XAIR
Q2 2027 - Four annual-meeting votes accompany the shift to a December 31 fiscal year-end.XAIRProxy filing
- Four proposals face stockholders amid a fiscal-year transition and new CEO pay terms.XAIRProxy filing
- Tankless nitric oxide therapy platform drives rapid growth and global market expansion.XAIRCorporate presentation
- Generation 2 device approval is set to unlock a $400M+ market with immediate deployment planned.XAIR12th Annual Cantor Fitzgerald Global Healthcare Conference
- Up to 5.4M shares registered for resale after a $10.2M private placement; focus on LungFit® growth.XAIRRegistration filing
- Flat revenue, improved margins, and strong outlook depend on FDA approval and new product launch.XAIRQ1 2027
- Revenue up 107% to $7.7M; Gen 2 launch and approval expected to drive major growth in 2027.XAIRQ4 2026
- Next-generation system and global partnerships position the company for accelerated growth by 2027.XAIRPiper Sandler 36th Annual Healthcare Conference